Sanofi Raises Profit Forecast on Diabetes, Orphan Drugs
This article is for subscribers only.
Sanofi raised its profit forecast for the year after reporting higher second-quarter earnings as it benefits from increased prices in the U.S. for its top-selling product, the diabetes medicine Lantus.
Earnings per share excluding some costs and currency swings will rise by 6 percent to 8 percent this year, Paris-based Sanofi said in a statement today, compared with a previous forecast for growth of 4 percent to 7 percent. Second-quarter profit climbed 3.9 percent.